Hikma Pharmaceuticals Public annual operating income
2020
2021
2022
2023
2024
2025
Hikma Pharmaceuticals Public Operating Income Growth & History (HIK)
Hikma Pharmaceuticals Public's operating income was $542.0M for fiscal 2025.
View full Hikma Pharmaceuticals Public company overviewHikma Pharmaceuticals Public annual operating income history
| Fiscal year | Period ended | Operating income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $542.0M | −$70.0M | −11.44% |
| 2024 | 2024-12-31 | $612.0M | $245.0M | +66.76% |
| 2023 | 2023-12-31 | $367.0M | $85.0M | +30.14% |
| 2022 | 2022-12-31 | $282.0M | −$300.0M | −51.55% |
| 2021 | 2021-12-31 | $582.0M | $3.0M | +0.52% |
| 2020 | 2020-12-31 | $579.0M | — | — |
Hikma Pharmaceuticals Public operating income trends
Over the last five fiscal years, Hikma Pharmaceuticals Public's operating income decreased from $579.0M to $542.0M, a change of −$37.0M.
About the metric
What operating income means
Operating income is the profit or loss a company generates from its core business after cost of revenue and operating expenses, but before non-operating items such as interest and income taxes.
Calculation and source
reported operating income
TickerStat standardizes operating income reported in company official filings for aligned fiscal periods. It is not adjusted EBIT, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Hikma Pharmaceuticals Public source filings ↗Community posts
Hikma’s epinephrine nasal spray advances into regulatory review
Hikma ($HIK) said regulators in the United States, Europe and the UK have accepted submissions for its investigational epinephrine nasal spray for review. The company has also filed in Canada and intends to expand submissions to additional ...